NMTR [NASD]
9 Meters Biopharma, Inc.
Index- P/E- EPS (ttm)-0.17 Insider Own1.10% Shs Outstand258.24M Perf Week-40.82%
Market Cap53.27M Forward P/E- EPS next Y-0.17 Insider Trans15.97% Shs Float249.02M Perf Month-49.42%
Income-42.70M PEG- EPS next Q-0.04 Inst Own29.50% Short Float6.16% Perf Quarter-62.47%
Sales- P/S- EPS this Y74.00% Inst Trans-4.66% Short Ratio5.24 Perf Half Y-76.31%
Book/sh0.12 P/B1.87 EPS next Y-6.30% ROA-80.50% Target Price3.00 Perf Year-79.74%
Cash/sh0.16 P/C1.43 EPS next 5Y- ROE-94.40% 52W Range0.22 - 1.46 Perf YTD-77.02%
Dividend- P/FCF- EPS past 5Y57.80% ROI- 52W High-84.60% Beta-2.31
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low1.76% ATR0.08
Employees21 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)32.65 Volatility24.45% 19.76%
OptionableYes Debt/Eq0.00 EPS Q/Q-71.00% Profit Margin- Rel Volume3.55 Prev Close0.26
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.93M Price0.22
Recom1.70 SMA20-52.44% SMA50-50.31% SMA200-71.66% Volume10,393,714 Change-13.77%
Jul-08-21Initiated BMO Capital Markets Outperform $5
Jun-04-21Initiated Citigroup Buy $3
Jul-01-22 07:52AM  
Jun-30-22 08:00AM  
07:00AM  
Jun-22-22 05:00AM  
Jun-21-22 08:00AM  
Jun-13-22 04:35PM  
May-19-22 08:00AM  
May-18-22 08:00AM  
May-16-22 07:00AM  
May-05-22 08:00AM  
Apr-20-22 09:00AM  
Apr-13-22 07:00AM  
Mar-23-22 07:00AM  
Mar-21-22 08:00AM  
Mar-09-22 08:00AM  
Mar-02-22 08:00AM  
Feb-28-22 04:15PM  
Feb-25-22 08:00AM  
Feb-09-22 08:00AM  
Feb-08-22 01:38PM  
Jan-24-22 08:00AM  
Jan-21-22 11:40AM  
Jan-18-22 08:00AM  
Jan-04-22 07:30AM  
Jan-03-22 07:30AM  
Dec-16-21 11:17AM  
Dec-15-21 07:30AM  
Nov-18-21 10:00AM  
Nov-15-21 07:30AM  
Nov-10-21 07:30AM  
Nov-09-21 07:30AM  
Oct-26-21 07:30AM  
Oct-19-21 07:30AM  
Oct-04-21 07:30AM  
Sep-27-21 07:30AM  
Sep-22-21 08:15AM  
Sep-15-21 08:15AM  
Sep-08-21 08:15AM  
Sep-01-21 08:15AM  
Aug-16-21 08:15AM  
Aug-12-21 08:30AM  
Aug-05-21 08:30AM  
Jul-19-21 08:30AM  
Jul-12-21 08:42AM  
Jul-08-21 07:30AM  
Jun-28-21 07:30AM  
Jun-22-21 10:43AM  
Jun-14-21 07:30AM  
Jun-09-21 07:30AM  
Jun-01-21 07:30AM  
May-26-21 08:30AM  
May-19-21 10:11AM  
May-18-21 10:15AM  
07:30AM  
May-17-21 07:30AM  
Apr-21-21 07:30AM  
Apr-19-21 07:30AM  
Apr-12-21 07:30AM  
Apr-05-21 04:15PM  
Mar-30-21 10:30PM  
04:14PM  
Mar-24-21 04:05AM  
Mar-22-21 04:00PM  
Mar-15-21 07:30AM  
Mar-10-21 07:30AM  
Mar-09-21 06:30AM  
Mar-01-21 07:30AM  
Feb-10-21 07:30AM  
Feb-04-21 08:12AM  
Feb-03-21 07:30AM  
Feb-01-21 07:30AM  
Jan-05-21 12:41PM  
Dec-21-20 07:30AM  
Dec-15-20 04:00PM  
Dec-11-20 08:30AM  
Dec-09-20 07:30AM  
Dec-07-20 07:30AM  
Dec-02-20 11:01AM  
Nov-16-20 07:30AM  
01:51AM  
Nov-09-20 07:30AM  
Nov-02-20 08:00AM  
Sep-08-20 08:30AM  
Aug-31-20 08:30AM  
Aug-13-20 04:30PM  
Aug-12-20 04:30PM  
Aug-04-20 09:30AM  
Jul-28-20 07:30AM  
Jul-21-20 07:45AM  
Jul-13-20 10:26AM  
Jul-06-20 04:15PM  
Jul-02-20 07:30AM  
Jun-29-20 07:30AM  
Jun-24-20 04:05PM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-05-20 06:30AM  
May-04-20 05:30PM  
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Constantino Michael T.DirectorMay 23Buy0.4816,0007,60860,509May 24 04:01 PM
Temperato JohnChief Executive OfficerMay 18Buy0.4550,00022,2851,302,522May 19 04:09 PM
Sirgo Mark ADirectorMay 18Buy0.47106,38350,0001,385,428May 19 04:01 PM
Sirgo Mark ADirectorMar 03Buy0.5886,45050,0021,279,045Mar 07 08:01 AM
Temperato JohnChief Executive OfficerMar 03Buy0.56100,00055,5901,252,522Mar 04 08:00 AM
Sirgo Mark ADirectorDec 02Buy0.8950,00044,5001,242,595Dec 03 07:34 AM
Temperato JohnChief Executive OfficerNov 18Buy1.0550,00052,5001,152,522Nov 19 07:31 AM
Sirgo Mark ADirectorNov 18Buy1.0620,00021,2001,192,595Nov 22 07:30 AM
Sitar Edward JChief Financial OfficerSep 14Buy1.2215,00018,300194,338Sep 15 08:12 AM
Sirgo Mark ADirectorSep 07Buy1.3673,52999,9991,172,595Sep 08 08:15 AM
Constantino Michael T.DirectorAug 24Buy1.1418,00020,52052,108Aug 26 08:18 AM
Sirgo Mark ADirectorAug 20Buy1.1025,00027,5001,099,066Aug 23 08:15 AM
Temperato JohnChief Executive OfficerAug 18Buy1.0525,00026,2501,102,522Aug 19 08:16 AM